Last reviewed · How we verify
Placebo combined with Letrozole
Letrozole is an aromatase inhibitor that blocks estrogen production in postmenopausal women, combined with placebo in this trial design.
Letrozole is an aromatase inhibitor that blocks estrogen production in postmenopausal women, combined with placebo in this trial design. Used for Hormone receptor-positive breast cancer in postmenopausal women (likely adjuvant or extended therapy setting).
At a glance
| Generic name | Placebo combined with Letrozole |
|---|---|
| Sponsor | Genor Biopharma Co., Ltd. |
| Drug class | Aromatase inhibitor |
| Target | Aromatase (CYP19A1) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Letrozole irreversibly inhibits the aromatase enzyme, which converts androgens to estrogen in peripheral tissues. By reducing circulating estrogen levels, it suppresses the growth of hormone receptor-positive breast cancer cells. The placebo component suggests this is a controlled trial comparing letrozole efficacy against placebo control.
Approved indications
- Hormone receptor-positive breast cancer in postmenopausal women (likely adjuvant or extended therapy setting)
Common side effects
- Hot flashes
- Arthralgia/joint pain
- Fatigue
- Headache
- Bone loss/osteoporosis
Key clinical trials
- A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) (PHASE3)
- Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer (PHASE3)
- A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer) (PHASE3)
- Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer (PHASE2, PHASE3)
- A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Palbociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Advanced Breast Cancer (PHASE3)
- Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer. (PHASE2)
- A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4] (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo combined with Letrozole CI brief — competitive landscape report
- Placebo combined with Letrozole updates RSS · CI watch RSS
- Genor Biopharma Co., Ltd. portfolio CI